Kenvue Surges in Trading Volume to Top March 30 Session Amid Divergent Institutional Bets

Market Snapshot

On March 30, 2026, Kenvue (KVUE) fell 1.60% in trading, with a total trading volume of $0.39 billion—a 86.84% increase compared to the previous day—ranking it as the top stock by volume for the session. The stock opened at $17.52 and is currently valued near its 50-day moving average of $18.01, while the 200-day moving average sits at $17.13. Kenvue’s stock remains within its one-year trading range of $14.02 to $25.17. Institutional ownership of the stock remains high at 97.64%, with multiple fund managers adjusting their positions in the fourth quarter.

Key Drivers

Recent institutional investor activity has played a notable role in shaping Kenvue’s stock dynamics. CIBRA Capital Ltd added 124,000 shares to its portfolio in Q4, valued at $2.14 million, representing 3.7% of the firm’s portfolio and its 12th-largest holding. Other funds also adjusted their stakes, with DLK Investment Management LLC reducing its position by 39.6% and Beacon Investment Advisory Services Inc. trimming its holdings by 12.6%. Conversely, several institutions, including Mather Group LLC and Global X Japan Co. Ltd., increased their ownership, with percentage gains ranging from 37.7% to 122.8%. These contrasting moves signal a mix of confidence and caution among institutional investors.

Kenvue reported earnings in early March that exceeded expectations, posting $0.27 EPS, up from $0.22 forecasted, and $3.78 billion in revenue, beating the $3.68 billion estimate. The results reflect a 3.2% year-over-year revenue increase, with $0.26 EPS in the same quarter in 2024. The company's return on equity (19.72%) and net margin (9.72%) also remain strong. However, its dividend payout ratio of 107.79%, despite offering an annualized yield of 4.7%, raises sustainability concerns. Analysts remain divided on the stock, with Jefferies cutting its rating to “Hold” and lowering its target to $18.00, while UBS and Citigroup raised their respective targets to $19.00 and $20.00.

The broader analyst consensus remains “Hold,” with an average price target of $19.58. Among the 16 analysts covering the stock, only three have assigned a “Buy” rating, while the rest either recommend a “Hold” or a “Neutral” stance. Weiss Ratings reaffirmed a “Hold (C-),” and Argus upgraded its rating to “Hold” in early March. Analysts appear to be recalibrating expectations for Kenvue in light of mixed earnings performance and a high payout ratio. This uncertainty may explain the recent volatility in the stock and the reluctance of some top analysts to recommend the stock over alternatives.

Despite recent institutional buying and outperforming quarterly results, Kenvue is trading at a price-to-earnings ratio of 22.75, a PEG ratio of 3.98, and a market cap of $33.57 billion. The firm's relatively low beta of 0.51 suggests it is less volatile than the broader market, potentially making it an attractive defensive holding. However, the high payout ratio and mixed analyst sentiment may limit its upside. The firm’s business model remains focused on consumer health and personal care products, with a portfolio of well-known brands under its belt.

Looking ahead, Kenvue’s ability to sustain earnings growth and manage its payout ratio will be critical for long-term investor confidence. Analysts are forecasting $1.14 in earnings per share for the fiscal year, and the company’s recent performance suggests it is capable of meeting these expectations. However, the mixed institutional activity and divergent analyst ratings underscore the market’s uncertainty. As of now, the stock appears to be in a holding pattern, with both investors and analysts waiting for stronger signals of growth or stability.